A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy

Doxorubicin remains an essential component of many cancer regimens, but its use is limited by lethal cardiomyopathy, which has been difficult to target, owing to pleiotropic mechanisms leading to apoptotic and necrotic cardiac cell death. Here we show that BAX is rate-limiting in doxorubicin-induced...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Cancer
Main Authors: Amgalan, Dulguun, Garner, Thomas P., Pekson, Ryan, Jia, Xiaotong F., Yanamandala, Mounica, Paulino, Victor, Liang, Felix G., Corbalan, J. Jose, Lee, Jaehoon, Chen, Yun, Karagiannis, George S., Sanchez, Luis Rivera, Liang, Huizhi, Narayanagari, Swathi-Rao, Mitchell, Kelly, Lopez, Andrea, Margulets, Victoria, Scarlata, Marco, Santulli, Gaetano, Asnani, Aarti, Peterson, Randall T., Hazan, Rachel B., Condeelis, John S., Oktay, Maja H., Steidl, Ulrich, Kirshenbaum, Lorrie A., Gavathiotis, Evripidis, Kitsis, Richard N.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7413180/
https://ncbi.nlm.nih.gov/pubmed/32776015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s43018-020-0039-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados